Biogen
Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy
January 19, 2026Research and Development Biogen, Neurology, Spinraza, spinal muscular atrophy
Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose regimen for the treatment of …
Biogen and Stoke report positive results for Dravet syndrome drug
July 17, 2025Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
June 28, 2024Business Services Alzheimers, Biogen, Eisai, Leqembi, Neurology, lecanemab
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …
FDA accepts Eisai’s Leqembi sBLA for early AD treatment
June 11, 2024Medical Communications Alzheimer's, Biogen, FDA, Neurology, sBLA
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted Eisai’s supplemental biologics license application …
BioGen to acquire Human Immunology Biosciences for $1.15bn
May 23, 2024Business Services Biogen, HI-Bio, Immunology, acquisition, immunology
BioGen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive agreement for Biogen to acquire …
Eisai shares new data for Leqembi for Alzheimer’s treatment
October 26, 2023Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …
Biogen’s biosimilar Tofidence approved by FDA
October 2, 2023Medical Communications Actemra, Biogen, FDA, Musculo-skeletal disorder, Tofidence
Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) as an intravenous formulation, a …
Biogen to acquire Reata Pharmaceuticals
July 31, 2023Business Services Biogen, Neurology, Reata Pharmaceuticals, acquisition
Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for …
FDA grants Alzheimer’s disease drug Leqembi full approval
July 7, 2023Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology
Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …
Biogen Phase III choroideremia study did not meet primary endpoint
June 15, 2021Manufacturing and Production Biogen, choroideremia, phase III
Biogen has announced that its investigational gene therapy study for the potential treatment of choroideremia did not meet its primary …
Biogen fails to meet primary endpoint in XLRP study
May 17, 2021Sales and Marketing Biogen, Clinical Trail
Biogen have released topline results from its Phase2/3 Xirius study of cotoretigene toliparvovec (BIIB112) as a gene therapy for patients …
FDA approves new IM administration route for Biogen’s MS drug Plegridy
February 2, 2021Manufacturing and Production Biogen, MS
The FDA has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy (peginterferon beta-1a) for the treatment …
Researchers and pharma companies partner to investigate new schizophrenia treatment
January 21, 2021Biogen, Boehringer Ingelheim
The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim are partnering to investigate a …
Biogen’s IM Plegridy gets EU approval
January 6, 2021Research and Development Biogen, multiple sclerosis
The European Commission has approved Biogen’s Plegridy (peginterferon beta-1a), a new intramuscular (IM) injection for the treatment of relapsing-remitting multiple …
Biogen agrees to pay $22m to settle kickback allegations
December 18, 2020Medical Communications Biogen, multiple sclerosis
Biogen has agreed to pay $22 million to put an end to an investigation into claims that it illegally used …
